Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Renal Cell 17Gastrointestinal Stromal Tumors 10Neoplasms 5Neoplasm Metastasis 4Multiple Myeloma 4Kidney Neoplasms 4Urologic Neoplasms 2Thyroid Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Osteosarcoma 2Meningioma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Kidney Diseases 2Gastrointestinal Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma 2Adenoma, Islet Cell 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thymoma 1Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rectal Neoplasms 1Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

atezolizumab 3Specimen Handling 2spartalizumab 1selinexor 1sargramostim 1pembrolizumab 1pazopanib 1fludarabine 1cediranib 1cabozantinib 1atropine sulfate-diphenoxylate hydrochloride drug combination 1anlotinib 1Zoledronic Acid 1Warfarin 1Vitamin B 6 1Thyroxine 1Tablets 1Sunitinib 1Rosuvastatin Calcium 1Radiotherapy 1Radiation 1Pyridoxine 1Promethazine 1Prochlorperazine 1Petrolatum 1Midazolam 1Lorazepam 1Loperamide 1Immunoglobulin G 1Ifosfamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Alveolar Soft Part × Sunitinib × 1 year × Clear all
NCT01391962 2026-02-02

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
34 enrolled 22 charts
Sarcoma

Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡